NanoViricides, Inc. (NYSE American: NNVC) has received National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is now preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP. Notably, the NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, which could enable rapid trial initiation if regulatory approval is received.
NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, according to NanoViricides. This oral formulation offers significant potential advantages over infusion-based therapies, particularly in resource-limited outbreak settings where intravenous administration is challenging. The company's broad-spectrum antiviral platform is designed to target host-cell features used by viruses, potentially providing a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines.
The approval marks a critical step in addressing the ongoing Bundibugyo ebolavirus outbreak in the DRC. Unlike the more common Zaire ebolavirus, Bundibugyo has no approved treatments or vaccines, making the development of effective therapies a public health priority. NanoViricides' oral gummy formulation could simplify administration and improve patient compliance, which is especially important in outbreak zones with limited healthcare infrastructure.
The implications of this trial extend beyond the current outbreak. If successful, NV-387 could become a key tool in the global health response to Ebola outbreaks, offering a portable, easy-to-administer treatment that can be deployed rapidly. The company's ability to leverage its existing drug supply in the DRC for both Mpox and Ebola trials demonstrates operational efficiency and a commitment to addressing multiple viral threats.
NanoViricides is a clinical-stage company specializing in nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for a range of viral infections, including RSV, COVID-19, influenza, Mpox, and Ebola. The company's technology is based on intellectual property licensed from TheraCour Pharma, Inc.
For more information on the latest news and updates regarding NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/MuxOe.
